Why in news?
A nationwide genetic study of endometriosis appeared in Scientific Reports on 5 September. It analysed 2,523 participants from an Indian multicentre case-control project. Researchers found shared susceptibility with other populations and several suggestive Indian signals. The findings concern risk, not a diagnostic genetic test.
What is endometriosis?
Endometriosis is a chronic disease involving tissue similar to the uterine lining. That tissue grows outside the uterus and can trigger inflammation. Scar tissue and adhesions may form over time. Common sites include the ovaries, pelvic lining and tissues around pelvic organs.
Symptoms differ widely between people and may change over time. They can include severe menstrual pain, chronic pelvic pain and heavy bleeding. Pain during sex, bowel movements or urination may occur. Fertility difficulties and persistent tiredness are also reported.
The World Health Organization estimates that about 190 million reproductive-age women and girls live with the condition globally. This is roughly ten per cent of that global group. The figure should not be presented as a measured Indian prevalence. National estimates need representative local data.
Why diagnosis can take time
Symptoms can resemble other gynaecological, urinary or digestive conditions. Some people also have extensive disease with limited pain. Doctors use medical history, examination and imaging to assess likely cases. Surgery may sometimes confirm disease or provide treatment, but it is not always required first.
Normalising severe menstrual pain can delay medical attention. Limited specialist access and fragmented referrals create further barriers. The World Health Organization notes long global diagnosis delays. Earlier recognition can support pain care, fertility planning and mental-health support.
There is currently no universal cure. Treatment can include pain medicines, hormonal therapy and surgery. Choices depend upon symptoms, disease extent and pregnancy plans. Care should be individualised because benefits, side effects and recurrence risks differ.
What is a genome-wide association study?
A genome-wide association study (GWAS) scans many common genetic variants across participants. Researchers compare variant frequencies between people with and without a condition. A statistical association can identify a nearby biological region. It does not prove that one variant directly causes disease.
Very large numbers of comparisons create false-positive risks. Scientists therefore use a strict genome-wide significance threshold. A weaker “suggestive” signal can guide future research but needs replication. Study size, ancestry and clinical definitions strongly influence the findings.
Most earlier endometriosis studies focused heavily on people of European ancestry. That imbalance can make risk models less reliable elsewhere. India also contains substantial genetic diversity. Including Indian participants can test shared biology and reveal signals needing local confirmation.
What the Indian study found
The study involved 2,523 participants from a nationwide multicentre case-control project. It identified twenty-one loci at a suggestive statistical level. The strongest signal lay on chromosome 13. It involved long non-coding ribonucleic acid (RNA) and regulatory elements upstream of the gene SHISA2.
No variant crossed the strict genome-wide threshold in the Indian discovery cohort alone. This is a crucial limitation. The twenty-one loci are not twenty-one confirmed disease genes. Larger independent Indian studies must test whether those associations recur.
The researchers also combined their data with a Japanese study. That meta-analysis replicated known significant associations near WNT4 and CDKN2B-AS1. Shared results across populations can strengthen confidence in common biological pathways. They do not eliminate meaningful population differences.
A risk score built from European studies showed comparable predictive performance in this cohort. A polygenic score combines small effects across many variants. Comparable performance is scientifically useful but does not establish clinical readiness. Prediction must be tested in larger, representative and independent groups.
Who conducted the work?
The project included the Endometriosis Clinical and Genetic Research in India (ECGRI) consortium. Hospitals across several Indian regions contributed participants. Lead institutional work came from the Indian Council of Medical Research. Its women’s health institute is based in Mumbai.
What the findings may enable
Validated genetic signals can reveal biological pathways for laboratory research. They may eventually improve risk estimation or identify treatment targets. That process usually takes years of replication and functional experiments. Current patients should not change treatment based upon these associations.
The study also draws attention to wider care gaps. Better awareness, trained clinicians and reliable referral pathways can help patients now. Pain and fertility services need coordination even before genetic discoveries reach practice. Research investment should strengthen both future science and present care.
Conclusion
The Indian study expands the ancestry base of endometriosis genetics and confirms some shared susceptibility. Its Indian-only signals remain suggestive, not proven causes or tests. Larger replication and biological work must follow. Meanwhile, timely diagnosis and individualised care remain the immediate public-health priorities.